These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24219039)

  • 1. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.
    Pincus T; Castrejón I
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S33-40. PubMed ID: 24219039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.
    Schipper LG; Vermeer M; Kuper HH; Hoekstra MO; Haagsma CJ; Den Broeder AA; van Riel P; Fransen J; van de Laar MA
    Ann Rheum Dis; 2012 Jun; 71(6):845-50. PubMed ID: 22210852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
    Castrejón I; Gibson KA; Pincus T
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on methotrexate as the anchor drug for rheumatoid arthritis.
    Pincus T; Gibson KA; Castrejón I
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S9-19. PubMed ID: 24219036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial.
    Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg BJ; Boesen M; Hetland ML; Christensen R; Møller J; Krogh NS; Stengaard-Pedersen K; Østergaard M
    Trials; 2015 Apr; 16():178. PubMed ID: 25896862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.
    Tymms K; Zochling J; Scott J; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Roberts L; Arnold M; Littlejohn G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):190-6. PubMed ID: 23983001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
    Graudal N; Jürgens G
    Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC
    BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoids in the treatment of rheumatoid arthritis: still used after 65 years.
    Bijlsma JW; Jacobs JW
    Ann N Y Acad Sci; 2014 May; 1318():27-31. PubMed ID: 24641732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug management of early rheumatoid arthritis - 2008.
    Sokka T; Mäkinen H
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):93-102. PubMed ID: 19233049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].
    Kobayashi S; Kanai Y
    Nihon Rinsho; 2002 Dec; 60(12):2351-6. PubMed ID: 12510361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.
    Urata Y; Uesato R; Tanaka D; Nakamura Y; Motomura S
    Ann Rheum Dis; 2012 Apr; 71(4):534-40. PubMed ID: 22021897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BeSt story: on strategy trials in rheumatoid arthritis.
    Klarenbeek NB; Allaart CF; Kerstens PJ; Huizinga TW; Dijkmans BA
    Curr Opin Rheumatol; 2009 May; 21(3):291-8. PubMed ID: 19318946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis.
    Jacobs JW
    Rheumatology (Oxford); 2012 Jun; 51 Suppl 4():iv3-8. PubMed ID: 22513146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.